CR10486A - Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico - Google Patents

Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico

Info

Publication number
CR10486A
CR10486A CR10486A CR10486A CR10486A CR 10486 A CR10486 A CR 10486A CR 10486 A CR10486 A CR 10486A CR 10486 A CR10486 A CR 10486A CR 10486 A CR10486 A CR 10486A
Authority
CR
Costa Rica
Prior art keywords
antagonists
receptor
growth factor
epidermal growth
pediatric patients
Prior art date
Application number
CR10486A
Other languages
English (en)
Inventor
Rowinsky Eric
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of CR10486A publication Critical patent/CR10486A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La combinacion de metodos de terapia para tratar tumores pediatricos mediante la administracion de un antagonista del EGFR y un agente quimioterapeutico. Los metodos incluyen tratar tumores pediatricos refractarios.
CR10486A 2006-07-27 2008-12-09 Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico CR10486A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83348706P 2006-07-27 2006-07-27

Publications (1)

Publication Number Publication Date
CR10486A true CR10486A (es) 2009-02-23

Family

ID=38982334

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10486A CR10486A (es) 2006-07-27 2008-12-09 Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico

Country Status (15)

Country Link
EP (1) EP2043688A4 (es)
JP (1) JP2009544736A (es)
KR (1) KR20090033841A (es)
CN (1) CN101484186A (es)
AU (1) AU2007279261A1 (es)
BR (1) BRPI0712368A2 (es)
CA (1) CA2654911A1 (es)
CR (1) CR10486A (es)
EA (1) EA200870603A1 (es)
EC (1) ECSP089011A (es)
MX (1) MX2008016187A (es)
NO (1) NO20085182L (es)
TN (1) TNSN08512A1 (es)
WO (1) WO2008014386A2 (es)
ZA (1) ZA200810600B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947461A4 (en) * 2019-03-27 2023-03-29 National Research Council of Canada ANTI-EGFRVIII ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF

Also Published As

Publication number Publication date
TNSN08512A1 (en) 2010-04-14
CA2654911A1 (en) 2008-01-30
KR20090033841A (ko) 2009-04-06
WO2008014386A2 (en) 2008-01-31
ZA200810600B (en) 2009-11-25
WO2008014386A3 (en) 2008-07-03
MX2008016187A (es) 2009-01-20
EA200870603A1 (ru) 2009-06-30
NO20085182L (no) 2009-04-24
AU2007279261A1 (en) 2008-01-31
EP2043688A4 (en) 2009-11-11
BRPI0712368A2 (pt) 2012-06-05
JP2009544736A (ja) 2009-12-17
EP2043688A2 (en) 2009-04-08
CN101484186A (zh) 2009-07-15
ECSP089011A (es) 2009-01-30

Similar Documents

Publication Publication Date Title
PH12015502155A1 (en) Myostatin antagonism in human subjects
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
SG10201902664RA (en) Combination therapy for treating cancer
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
MX344355B (es) Uso de inhibidores de erbb3 en el tratamiento de canceres de mama triple negativos y de tipo basal.
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
NZ587706A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
NZ603958A (en) Method of treating a musculoskeletal disorder or connective tissue disorder in a subject with prostate cancer with the GNRH antagonist Degarelix
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
NZ712184A (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
BRPI0518619A2 (pt) mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica
PH12015502266A1 (en) Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
RU2013126036A (ru) Способ лечения опухолей
CR10486A (es) Tratamiento de tumores en pacientes pediatricos con antagonistas del receptor del factor de crecimiento epidermico
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX349767B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)